Drugs / Ribavarin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02204475 Comparator | Nov 2014 → Jun 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ribavarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02204475 ↗ |
| Route | Oral | “Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.” NCT02204475 ↗ |